Kathleen Behrens - Sarepta Therapeutics Independent Director
SRPT Stock | USD 133.66 3.03 2.32% |
Director
Dr. M. Kathleen Behrens, Ph.D., is Independent Chairwoman of the Board of the Company. Dr. Behrens has served as a member of our Board since March 2009 and as Chairwoman of the Board since April 2015. She also serves as member of our research and development committee and as a member of and chair of our audit committee. Dr. Behrens served as a member of the Presidents Council of Advisors on Science and Technology from 2001 to early 2009 and as Chairwoman of PCASTs Subcommittee on Personalized Medicine. She has served as a publicmarket biotechnology securities analyst as well as a VCist focusing on healthcare, technology and related investments. Dr. Behrens was instrumental in the founding of several biotechnology companies, including Protein Design Labs, Inc. and COR Therapeutics, Inc. She worked for Robertson Stephens Co. from 1983 through 1996, serving as a General Partner and Managing Director. Dr. Behrens continued in her capacity as a General Partner for selected venture funds for RS Investments, an investment management and research firm, from 1996 through December 2009, after management led a buyout of that firm from Bank of America. While Dr. Behrens worked at RS Investments, from 1996 to 2002, she served as a Managing Director at the firm and, from 2003 to December 2009, she served as a consultant to the firm. From 1997 to 2005, she was a director of the Board on Science, Technology and Economic Policy for the National Research Council, and from 1993 to 2000 she was a Director, President and Chairwoman of the National VC Association. Since December 2009, Dr. Behrens has worked as an independent life sciences consultant and investor. Dr. Behrens was a director of Amylin Pharmaceuticals, Inc. from June 2009 until Amylins sale in August 2012 to BristolMyers Squibb Company. Dr. Behrens also served as the President and Chief Executive Officer of KEW Group Inc., a private oncology services company. since 2015.
Age | 65 |
Tenure | 9 years |
Professional Marks | Ph.D |
Address | 215 First Street, Cambridge, MA, United States, 02142 |
Phone | 617 274 4000 |
Web | https://www.sarepta.com |
Sarepta Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.0189) % which means that it has lost $0.0189 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0202 %, meaning that it created $0.0202 on every $100 dollars invested by stockholders. Sarepta Therapeutics' management efficiency ratios could be used to measure how well Sarepta Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.17 in 2024. Return On Capital Employed is likely to drop to -0.11 in 2024. At this time, Sarepta Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 3.4 B in 2024, whereas Non Current Liabilities Other is likely to drop slightly above 39 M in 2024.Similar Executives
Showing other executives | DIRECTOR Age | ||
Richard Levy | Madrigal Pharmaceuticals | 60 | |
Emma Reeve | PTC Therapeutics | 57 | |
Ryan Maynard | Iovance Biotherapeutics | 48 | |
Stephanie Okey | PTC Therapeutics | 58 | |
Michael Weiser | Iovance Biotherapeutics | 55 | |
Geoffrey McDonough | PTC Therapeutics | 45 | |
John Brancaccio | Hepion Pharmaceuticals | 69 | |
Wayne Rothbaum | Iovance Biotherapeutics | 50 | |
David Milligan | Madrigal Pharmaceuticals | 77 | |
David Southwell | PTC Therapeutics | 57 | |
Robert Wilson | Madrigal Pharmaceuticals | 75 | |
Ronald Renaud | PTC Therapeutics | 45 | |
Bruce Leith | Terns Pharmaceuticals | N/A | |
James Daly | Madrigal Pharmaceuticals | N/A | |
Dawn Svoronos | PTC Therapeutics | 71 | |
MD FACP | Hepion Pharmaceuticals | N/A | |
Albert Sisto | Terns Pharmaceuticals | 63 | |
Adam Koppel | PTC Therapeutics | 45 | |
Kathy Rouan | Viking Therapeutics | 56 | |
Sanford Hillsberg | Iovance Biotherapeutics | 68 | |
Sarah Payne | Terns Pharmaceuticals | 41 |
Management Performance
Return On Equity | 0.0202 | ||||
Return On Asset | -0.0189 |
Sarepta Therapeutics Leadership Team
Elected by the shareholders, the Sarepta Therapeutics' board of directors comprises two types of representatives: Sarepta Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sarepta. The board's role is to monitor Sarepta Therapeutics' management team and ensure that shareholders' interests are well served. Sarepta Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sarepta Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Edward Kaye, Senior Vice President Chief Medical Officer | ||
Alexander Cumbo, Vice President Head of Commercial | ||
William Ciambrone, Ex Operations | ||
Dallan Murray, Executive Officer | ||
Hans Wigzell, Independent Director | ||
Michael Bonney, Director | ||
Sandesh Mahatme, CFO, Chief Accounting Officer and Sr. VP | ||
Ryan JD, General VP | ||
Jayant Aphale, Senior Vice President - Technical Operations | ||
Mary Gray, Director | ||
Douglas Esq, CEO President | ||
Anthony Chase, Independent Director | ||
Douglas Ingram, President CEO | ||
Gilmore ONeill, Senior Vice President Chief Medical Officer | ||
JeanPaul Kress, Director | ||
Joan Wood, Vice President - Human Resources | ||
Alison Nasisi, Executive Officer | ||
Bilal Arif, Executive Officer | ||
Ryan Brown, Gen VP | ||
Richard Barry, Independent Director | ||
Gil Price, Independent Director | ||
Catherine StehmanBreen, Senior Vice President Chief Medical Officer | ||
David Howton, Sr. VP, General Counsel and Corporate Secretary | ||
Mary Jenkins, Sr Relations | ||
Ian Estepan, Executive CFO | ||
Guriqbal Basi, Senior Vice President Chief Scientific Officer | ||
Will Tilton, Head VP | ||
William Goolsbee, Non-Executive Independent Chairman of the Board | ||
Louise RodinoKlapac, Chief VP | ||
Claude Nicaise, Independent Director | ||
Kathleen Behrens, Independent Director | ||
Diane Berry, Executive Officer | ||
Erin Cox, IR Contact | ||
Shamim Ruff, Senior Vice President - Regulatory Affairs and Quality | ||
Francesca Nolan, Executive Communications |
Sarepta Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sarepta Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.0202 | ||||
Return On Asset | -0.0189 | ||||
Profit Margin | 0.01 % | ||||
Operating Margin | 0.08 % | ||||
Current Valuation | 12.35 B | ||||
Shares Outstanding | 94.52 M | ||||
Shares Owned By Insiders | 4.39 % | ||||
Shares Owned By Institutions | 87.02 % | ||||
Number Of Shares Shorted | 4.87 M | ||||
Price To Earning | (20.43) X |
Currently Active Assets on Macroaxis
LAAC | Lithium Americas Corp | |
F | Ford Motor | |
CHPT | ChargePoint Holdings | |
AXL | American Axle Manufacturing | |
ICLN | iShares Global Clean |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sarepta Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more information on how to buy Sarepta Stock please use our How to Invest in Sarepta Therapeutics guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Complementary Tools for Sarepta Stock analysis
When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
CEOs Directory Screen CEOs from public companies around the world | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Content Syndication Quickly integrate customizable finance content to your own investment portal |
Is Sarepta Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sarepta Therapeutics. If investors know Sarepta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sarepta Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.43 | Revenue Per Share 14.953 | Quarterly Revenue Growth 0.631 | Return On Assets (0.02) | Return On Equity 0.0202 |
The market value of Sarepta Therapeutics is measured differently than its book value, which is the value of Sarepta that is recorded on the company's balance sheet. Investors also form their own opinion of Sarepta Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sarepta Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sarepta Therapeutics' market value can be influenced by many factors that don't directly affect Sarepta Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sarepta Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sarepta Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sarepta Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.